Humira's approval widened to include ulcerative colitis

Humira's approval widened to include ulcerative colitis

(HealthDay)—Humira (adalimumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe ulcerative colitis in adults, the agency said Friday.

Humira—an anti- agent that's designed to suppress abnormal inflammatory and immune responses—has already been approved to treat a host of conditions, including , Crohn's disease, and plaque psoriasis.

Ulcerative colitis affects about 620,000 people in the United States, according to the U.S. National Institutes of Health.

The most common side effects of Humira include infection, injection-site reaction, headache, and rash, according to an FDA news release.

The drug is manufactured by Abbott Laboratories, based in North Chicago, Ill.

More information: The U.S. National Library of Medicine has more about ulcerative colitis.

Related Stories

Pfizer says patient died in oral RA drug study

date Apr 22, 2011

(AP) -- Pfizer Inc. confirmed that one patient who was taking its drug candidate tofacitinib, a pill designed to treat rheumatoid arthritis, died during a recent clinical trial and said the death was connected to the drug.

FDA: Arthritis drugs pose cancer risk to children

date Aug 04, 2009

(AP) -- Federal regulators on Tuesday added stronger warnings to a group of best-selling drugs used to treat arthritis and other inflammatory diseases, saying they can increase the risk of cancer in children and adolescents.

Marqibo approved for ph- acute lymphoblastic leukemia

date Aug 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with Philadelphia chromosome negative acute lymphoblastic leukemia ...

Recommended for you

Rising antibiotic shortages raise concerns about patient care

date Apr 23, 2015

Shortages of key antibiotics, including gold-standard therapies and drugs used to treat highly resistant infections, are on the rise, according to a new study of shortages from 2001 to 2013 published in Clinical Infectious Di ...

Study supports HPV vaccination guidelines

date Apr 21, 2015

(HealthDay)—New research finds that young women who get the HPV vaccine gain significant protection against infection in three parts of the body if they haven't already been exposed to the human papillomavirus.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.